1. Her2-positive breast cancer: updating current best practice

3. Program Overview

4. Case #1: Neoadjuvant Setting

5. Case #1: Treatment Recommendations

6. NeoSphere: Study Design and pCR Results

7. PFS: All Arms of Therapy, ITT Population Time From Randomization to Progressive Disease, Disease Recurrence, or Death

8. TRYPHAENA: Cardiac Tolerability During the Study in the Safety Period

9. DFS: All Arms of Therapy, ITT Population Time From Date of Surgery to Disease Progression or Death

10. Case #2: Adjuvant Setting

11. Case #2: Treatment Recommendations

12. Adjuvant Paclitaxel and Trastuzumab: Phase 2 Data

13. Case #3: Advanced First-Line

15. PERUSE: First-line Pertuzumab, Trastuzumab Plus Investigator’s Choice of Taxane Therapy

16. Case #4: Second-Line Metastatic

17. Case #3: Treatment Considerations

18. Case #4: Second-Line Metastatic — Case Evolution

19. Case #4: Second-Line Metastatic — Case Evolution

20. EMILIA: CNS Metastases at Baseline and Progression

22. Abbreviations

23. Abbreviations

24. Abbreviations

25. Abbreviations